PLASMIC Score — TTP Risk Stratification
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low risk0–4
- Intermediate risk5–5
- High risk6–7
The PLASMIC Score — TTP Risk Stratification calculates predicting severe ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura. Key inputs include platelet low. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
The PLASMIC score predicts severe ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura. 7 items, 1 point each. Total 0-7.
Clinical Indication
The PLASMIC Score — TTP Risk Stratification is indicated for bedside clinical practice to support The PLASMIC score predicts severe ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura. 7 items, 1 point each. Total 0-7.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
PLASMIC = 1 point each for: platelets <30x10^9/L; hemolysis (reticulocytosis, undetectable haptoglobin, or indirect bilirubin >2 mg/dL); no active cancer; no transplant history; MCV <90 fL; INR <1.5; creatinine <2.0 mg/dL. Range 0-7.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| platelet_low | integer | Yes | Platelet count <30 x10^9/L |
| hemolysis | integer | Yes | Hemolysis (reticulocytosis, undetectable haptoglobin, or indirect bilirubin >2 mg/dL) |
| no_cancer | integer | Yes | No active cancer |
| no_transplant | integer | Yes | No history of stem-cell or solid-organ transplant |
| mcv_low | integer | Yes | MCV <90 fL |
| inr_low | integer | Yes | INR <1.5 |
| creatinine_low | integer | Yes | Creatinine <2.0 mg/dL |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–4 | Low risk | Low risk (0-4) |
| 5–5 | Intermediate risk | Intermediate risk (5) |
| 6–7 | High risk | High risk (6-7) |
Evidence-Based References (EBM)
- Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies. Lancet Haematol. 2017;4(4):e157-e164.